Overview

Brexpiprazole in Borderline Personality Disorder

Status:
Completed
Trial end date:
2021-04-14
Target enrollment:
Participant gender:
Summary
The primary objective of the proposed study is to evaluate the safety and efficacy of Brexpiprazole in adults with borderline personality disorder (BPD). The hypothesis to be tested is that brexpiprazole will be more effective and well tolerated in adults with BPD compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Collaborator:
Otsuka America Pharmaceutical
Treatments:
Brexpiprazole